NMRA vs RARE · $283.5M cap vs rev $560.2M
Neumora Therapeutics, Inc. (NMRA) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Neumora Therapeutics, Inc. (NMRA) is a biotechnology company listed on NASDAQ.
Ultragenyx (RARE) is a biotechnology company listed on US.
NMRA does not have a complete income-statement cache yet.
Latest reported RARE revenue for 2024-12-31 was $560.2M. Net income was -$569.2M. Revenue was up 29.0% from 2023-12-31 to 2024-12-31. RARE currently screens at market cap $2.79B.
NMRA currently screens at market cap $283.5M. RARE currently screens at market cap $2.79B.
Not investment advice. Open the NMRA and RARE stock pages for the full models.
Not investment advice.